Bachema Laboratório de Análises Ambientais

O Grupo Vittia, empresa brasileira de biotecnologia e insumos agrícolas, está presente há 50 anos no país com a missão de permitir aos produtores, ganhos de rentabilidade por área e melhoria do balanço socioambiental, entregando excelência em produtos e serviços para a agricultura.

Sempre expandindo sua atuação a favor do agronegócio por meio de pesquisa, tecnologia e desenvolvimento, o Grupo, dedicado à produção de insumos de alta tecnologia para a agricultura, conta com diversos produtos nas linhas de inoculantes, adjuvantes, acaricidas, condicionadores de solo, defensivos biológicos, fertilizantes foliares, fertilizantes organominerais, micronutrientes granulados para solo e sais para a agricultura e pecuária.

Atuando por meio das marcas Vittia, Biosoja, Samaritá, Biovalens e Vitória Fertilizantes, o Grupo possui sete unidades industriais localizadas em São Joaquim da Barra (2), Serrana, Ituverava e Artur Nogueira, no estado de São Paulo, e em Uberaba e Patos de Minas, no estado de Minas Gerais.

Comprometido com os princípios da sustentabilidade, o Grupo visa criar valor por meio da inovação e ampliação de negócios estratégicos no mercado.

CEMSA is a company that provides laboratory services, using mass spectrometry as a tool for the development of efficient analytical methods, providing quick answers with high reliability to the several areas of the chemical sciences, pharmaceutical, biological and related.

FARMACORE is a technology-based company created to conduct R&D&I of biotechnological processes and products for the human and veterinary area.

The company develops and adds value to innovative biotechnological and immunobiological products throughout the various phases of development, from project conception to production of biomolecules.

ECLA is an Academic Research Organization devoted to provide support and expertise for the conduct of clinical trials in Latin America.

With headquarters located in Rosario, Argentina, offices in Montevideo -Uruguay and local representations in Sao Paulo-Brazil, Temuco-Chile, Lima-Peru, Bucaramanga-Colombia and Quito-Ecuador, ECLA leads the coordination of clinical trials in the region.

In the early days of 1987, ECLA designed and conducted the first full-scale clinical trial in the setting of acute myocardial infarction in collaboration with Oxford University, UK. Since then, more than 30.000 patients have been enrolled in controlled clinical trials.

ECLA helps the pharmaceutical industry in its efforts to bring cutting edge therapies to the marketplace by providing a wide range of services:
- Academic leadership
- Project, site and regulatory management
- Monitoring
- Quality Assurance
- Pharmacy
- Financial and legal assistance
- Data management and statistical support

ECLA has been collaborating with worldwide academic organizations and pharmaceutical companies for the design, set up and conduct of clinical trials in the following therapeutic areas: cardiology, diabetes, epidemiology, oncology, neurology, pneumology and vaccines.

ReSolution Latin America is a clinical research solutions provider completely specialized in supporting our sponsors with their clinical development programs in the Latin American region. We provide our Sponsors with the opportunity to work with a credible regional niche CRO provider that is able to successfully:

• Understand the expectations of international clients, as well as the requirements and demands of international clinical protocols.
• Work locally and regionally to execute and deliver to these standards ensuring that the data that stems from Latin America can be integrated into the global data sets and used by our Sponsors for international regulatory purposes.

Our expertise and infrastructure across the Latin American region enables us to offer our Sponsors access to all the advantages the region has to offer for clinical development (quality data, high enrollment potential, shortening of development timelines and cost) whilst minimizing potential pitfalls.

Working exclusively through our own, fully-owned legal entities and with our own staff (no contractors/freelancers)- since our inception in 2007- we have enrolled in the region of 14,000 study participants across the board in terms of therapeutic areas, disease-types, product types and study complexities.

We understand local and regional idiosyncrasies in a region where one size does not fit all.